※Sunovion COPD Event: CHEST Annual Meeting 2017, Stop by booth. ・Don't miss industry experts speaking on COPD management. ・October 30 (Today) at the MetroToronto Convention Center, CHEST Exhibit Hall, Learning Theater 1.
※Pluristem: Proposes to Launch a Public Offering of Common Stock on the Tel Aviv Stock Exchange After Concluding an Israeli Institutional Investors Tender. (10/29) Haifa, Israel - October 29, 2017 - Pluristem Therapeutics Inc. announced today that in connection with its proposed public offering of its shares of Common Stock on the Tel Aviv Stock Exchange it has concluded an Israeli institutional investors tender. In the tender the Company has received overall commitments from Israeli institutional investors and accredited investors for the purchase of 8,873,700 shares in different prices for a total amount of approximately $15 million and chose to accept commitments of 7,123,700 shares at a purchase price of $1.61 (or NIS 5.70 per share) for a total amount of approximately $11.5 million. Upon the approval of the TASE, the Company intends to conduct a public offering of its shares on the TASE on Monday, October 30, 2017 at a minimum purchase price of $1.61, for up to 9,000,000 shares in the aggregate. The closing of the offering is expected to occur on or about October 31, 2017, subject to customary closing conditions.
※iTunes: "MoleculE 2 VR" by AppMinded Ltd. (10/27 Released) This app is only available on the App Store for iOS devices. Description: Under attack! Bacteria are invading your body! Explore in Virtual Reality the magic behind the immune response in your body! Have a close look at white blood cells fighting a bacterial invasion. Learn about the important role of the chemokine receptor CCR9: a key player in the recruitment of white blood cell to the gut. "MoleculE 2 VR" includes 3D information derived from X-ray crystal structure data solved by HeptaresTherapeutics Scientists (Intracellular allosteric antagonism of the CCR9 receptor. Nature. 2016 Dec 15;540(7633):462-465. doi: 10.1038/nature20606.) 0099山師さん＠トレード中 (ｱｳｱｳｴｰT Sa23-Eec1)2017/10/30(月) 22:03:18.91ID:CNb18gqka>>98 時間外取引でPluristemの株価下がってんのこれだよね 時間前取引: 1.70Price decrease0.27 (13.71%) 0100山師さん＠トレード中 (ﾜｯﾁｮｲ a969-0QAE)2017/10/31(火) 00:25:56.24ID:y/alMIB10>>86 マジか 0101山師さん＠トレード中 (ﾜｯﾁｮｲW 1111-t4Ij)2017/10/31(火) 00:40:23.13ID:oUTHe1u30 大日本住友販売力皆無かよ 0102山師さん＠トレード中 (ﾜｯﾁｮｲ 898e-AYwW)2017/10/31(火) 06:00:07.94ID:9TcvHnBD0 ※Pluristem announces pricing of public offering of common stock on the Tel Aviv Stock exchange. Haifa, Israel - October 30, 2017 - Pluristem Therapeutics Inc. announced today the pricing of its previously announced public offering of 9,000,000 shares of common stock on the Tel Aviv Stock Exchange (TASE) at a price of $1.67 (NIS 5.90) per share with expected gross proceeds to the Company of $15.1 million. The Company received overall orders for the purchase of approximately 13,500,000 shares at different prices for a total aggregate amount of approximately $21.8 million and chose to accept orders in the aggregate amount of $15.1 million for the 9,000,000 shares offered. Due to the over subscription, the previously reported minimum share price increased from $1.61 to $1.67 per share. The closing of the offering is expected to occur on or about October 31, 2017, subject to customary closing conditions. The Company intends to use the net proceeds of the offering for research and product development activities, clinical trial activities, investment in capital equipment and for working capital and other general corporate purposes. 0103山師さん＠トレード中 (ﾜｯﾁｮｲ 898e-AYwW)2017/10/31(火) 06:00:40.19ID:9TcvHnBD0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares has over 115 employees in the UK and 6 employees in Zurich. UK be relocating to the Cambridge area in "July 2018." The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline. ・・・ ※ClinicalTrials: HTL0018318: "Completed: 2017/8/20.", HTL0016878: "Recruiting: 2017/8/25." (9/6update) ※Pluristem: "Closing JV deal with Sosei: H2 2017", "Japan pivotal study initiation: H1 2018" (Change, 9/17up) ※Heptares: Wave2 Proprietary Pipeline: "Multiple Candidates Entering Clinic from H2 2017" (9/27update) ※ClinicalTrials: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9". (10/18update) ※SOSEI：米国におけるSeebri Neohaler Inhalation Powderの販売開始。(10/20) ※Novartis: Ultibro Q3 (101 million, +3% cc), 9M 2017 (291 million, +8% cc), Seebri Q3 (37 million, +2% cc), 9M 2017 (109 million, +2% cc). (10/24) ※Vectura: Q3 Total reported net sales for Ultibro grew 6%. In Europe, Ultibro grew 18% year-on-year. (10/24) ※Fiona Marshall: Excited to be Attending Zurich GPCR Day. ※Heptares: Some Great GPCR, GPCRs Science on Show Today. (10/25) ※Heptares Zurich: Seeking an Senior Protein Biochemist to Join Our Site in Zurich Working. "Closing 2017/11/15" (10/27) ※Pluristem: Upcoming: "Initiate pivotal trials, CLI in Japan", "Japan- Finalize Joint Venture" (10/29update) ※大日本住友製薬 第2四半期決算：北米COPD新製品群：2Q実績2百万ドル、下期予想4百万ドル(5億円)、通期予想6百万ドル(7億円)。(10/30) ※大日本住友製薬 10/31決算説明会資料：収益基盤の強化に向けて、北米COPD新製品群の効率的販売体制構築：サノビオンMR+コントラクトMR。(10/30up) ・・ ※第一三共 平成30年3月期第2四半期決算発表/決算説明会: (本日) ※Pfizer Quarterly Corporate Performance Q3 2017: (本日) ※Allergan Q3 2017 Earnings Conference Call: (11/1) ※Teva Q3 2017 Earnings Conference Call: (11/2) ※AstraZeneca Year-to-date and Q3 2017 Results: (11/9) ※SOSEI 平成30年3月期第2四半期決算発表: (11/9) ・・・ 0104山師さん＠トレード中 (ﾜｯﾁｮｲ 898e-AYwW)2017/10/31(火) 06:01:22.02ID:9TcvHnBD0 ※SOSEIの成長相場の動向： 2010/12/30 (終値_1350) 売残高_2740 買残高 _607100 ・(2010/10/15※最安値_650、2010/5/22最高値1545) 2011/12/30 (終値_1271) 売残高____0 買残高 _518100 ・(2011/3/15※最安値_693、2011/6/30最高値1680) 2012/12/21 (終値_2093) 売残高__100 買残高 _653600 ・(2012/6/6※最安値_950、2012/9/7最高値2967) 2013/12/20 (終値_4045) 売残高28500 買残高 _833300 ・(2013/1/4※最安値2050、2013/5/7最高値6100) 2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron･Seebri米国承認)※[次なる飛躍]ステージへ 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場] 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ 2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移] 2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380)※[仕掛け、振るい場・拾い場]へ 2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち] 2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(7/31安値11280、8/24,29安値8860、9/6※最安値8590)※[振るい・拾い場も順調に推移] 2017/10/20 (終値_9810) 売残高____0 買残高 1746900 ・(10/4安値9090、10/10安値9570、10/19安値9740) ※[時間軸調整終盤、予定通りに推移] 2017/10/27 (終値10230) 5日線乖離(+0.59%) 25日線乖離(+5.39％) 75日乖離(+1.75％) 200日線乖離(-9.33％) (安値10190) ・(10/23安値9820) 2017/10/30 (終値10400) 5日線乖離(+1.68%) 25日線乖離(+6.62％) 75日乖離(+3.67％) 200日線乖離(-7.70％) (安値10240)
透明アボーン知らない低脳。 死ねばいいのに。。 0120山師さん＠トレード中 (ﾜｯﾁｮｲ 898e-AYwW)2017/10/31(火) 23:00:05.33ID:9TcvHnBD0 ※Pluristem_HP_From the Media: A Glimpse from the Media. (1 Title Added: 10/31up) "Health Ministry Approves Pioneering Placenta-Cell Therapy for Blood Disorders. " Jerusalem Post, October 29, 2017 Patients suffering from bone-marrow failure could have better quality of life and longer survival rates following approval by the Health Ministry to extend a clinical trial of a new placenta-based cell therapy in Israeli hospitals. The ministry approved the launch of a phase I trial of Pluristem Therapeutics Inc.’s PLX-R18 cell therapy as treatment for insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT, or bone-marrow transplant). The trials will take place at Hadassah Medical Center in Jerusalem and Rambam Hospital in Haifa. A similar trial was approved by the United States FDA, and recruitment is ongoing in the US. Up to 30 patients will be recruited in both countries in the two studies. Previous studies with PLXR18 placenta cells have yielded promising results, according to Pluristem’s co-CEO and chairman Zami Aberman. ・・・ The cell therapy currently falls under the umbrella of compassionate use, the treatment of a seriously ill patient using an unapproved drug when no other treatments are available, he said. On average, more than 13,000 Americans are diagnosed annually with myelodysplastic syndromes, a group of blood disorders associated with abnormal blood-cell production and bone-marrow failure. Further, bone-marrow failure can also be a side effect of radiation or chemotherapy treatment for cancer. The average length of survival depends on each case, but the prognosis is often poor, and usually the patients require HCT. Additionally, according to the Institute for Justice, at least 3,000 people in need of a bone-marrow transplant die each year because they cannot find a matching donor. With PLX-R18, because the cells are grown using Pluristem’s proprietary 3-D micro-environmental technology and are an “off-theshelf” product, the process does not require the matching of tissues between donor and recipient and may support grafting from an unmatched donor. Rather than using stem cells as a replacement part, PLXR18 cells secrete a range of specific proteins that trigger the regeneration of bone-marrow hematopoietic cells, thereby supporting the recovery of blood-cell production This is not the company’s only placenta-based therapy. Pluristem’s PLX-R18 cells are in late-stage development as a treatment for acute radiation syndrome in conjunction with the US National Institute of Health, the Defense Department and the FDA. Aberman said this approval could fast-track the cell-product use for other indications related to damaged hematological systems, resulting in improved treatment for millions of people. “We are very pleased with the Israeli Ministry of Health’s vote of confidence in our innovative therapies,” Aberman said. 0121山師さん＠トレード中 (ﾜｯﾁｮｲ 898e-AYwW)2017/10/31(火) 23:00:20.85ID:9TcvHnBD0 ※米国特許：CGRP Receptor Antagonists. (10/31公開) ・Document Type and Number: United States Patent 9802935 B2 ・Publication Date: 10/31/2017 ・Assignee: Heptares Therapeutics Limited Abstract: The disclosures herein relate to novel compounds of formula embedded image wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
これ事実なんか？ 0223山師さん＠トレード中 (ｽﾌﾟｯｯ Sd62-gizm)2017/11/02(木) 21:39:28.90ID:Pzr2QeC3d テバ！ 0224山師さん＠トレード中 (ﾜｯﾁｮｲ 3d8e-zM96)2017/11/02(木) 22:00:11.33ID:bODnGivl0 ※MiNA Therapeutics‏ 3時間前：Honoured to be Awarded £400k Grant by Iinnovate UK Working with Link LGC Group to Develop Liver Directed Gene Activation Medicines. ※Robert Habib 3時間前：Exciting New area of Research in Collaboration with LGCGroup LINK. MiNA Therapeutics.
※MiNA: Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK. (11/2)
London and Bellshill, United Kingdom – 2 November, 2017 – MiNA Therapeutics, the pioneer in RNA activation therapeutics, and LGC LINK, the oligonucleotide synthesis reagent manufacturer, and part of the Genomics division of LGC, today announced that Innovate UK has awarded the two companies a grant to develop liver targeted gene activation therapies for the treatment of liver diseases. The grant of up to approximately £400,000, with additional funding from MiNA and LGC LINK, will support a two-year research project.
Small activating RNAs (saRNAs) are an emerging class of medicines that restore normal function to patients’ cells by activating expression of specific genes. In 2016 MiNA Therapeutics initiated the OUTREACH Phase I clinical study of lead program, MTL-CEBPA, in severe liver cancer. LGC LINK has developed cutting edge chemistry and linker technologies to enable the targeted delivery of RNA compounds to liver cells.
If successful, the research project may enable the future discovery of liver targeted saRNA drug candidates with distinct benefits over those currently in development including a more convenient route of administration and a broader therapeutic safety window. Under the terms of the collaboration MiNA will have exclusive use of the results for oligonucleotide approaches that activate gene expression. LGC LINK will have exclusive use of the results for oligonucleotide approaches that inhibit gene expression.
“We are extremely pleased to be selected by Innovate UK for this prestigious grant,” commented David Blakey, CSO of MiNA Therapeutics. “We are excited to work with LGC LINK to expand the possibilities of saRNAs for the treatment of liver diseases.”
Catherine McKeen, Head of Chemistry of LGC LINK said, “Oligonucleotide therapeutics have always been of particular interest at LINK. This exciting collaboration with MiNA Therapeutics enables us to further develop modifiers and linkers to improve targeted delivery and cellular uptake of RNA oligonucleotide based drugs.”
This grant is part of the Biomedical Catalyst scheme funded by Innovate UK, The Medical Research Council and Scottish Enterprise. 0225山師さん＠トレード中 (ﾜｯﾁｮｲW 9911-OkHc)2017/11/02(木) 22:33:10.33ID:pUMcQG1l0 chiよ和訳してくれたらお前を許そう。 0226山師さん＠トレード中 (ﾜｯﾁｮｲW 62ed-Cv1d)2017/11/02(木) 22:40:36.44ID:h36E6Dqb0 専用スレですよここ 0227山師さん＠トレード中 (ﾜｯﾁｮｲW e11a-U3Tt)2017/11/02(木) 22:46:50.22ID:jdrtt0gu0 ここしか伸びてないってことは、chi嫌っている奴は少人数しかいないということだな 0228山師さん＠トレード中 (ﾜｯﾁｮｲ c2f4-T3Jr)2017/11/02(木) 23:29:53.96ID:cppTm4L10 chiはいつも罵声を浴びながらも書き込み続けてるのに あっちのスレには書き込まなくてうけるんだが
ホンモノの基地外だろw 0233山師さん＠トレード中 (ｽﾌﾟｯｯ Sd62-gizm)2017/11/03(金) 02:42:22.84ID:uWmMPTTVd>>225 英語読めない低脳お断り 向こう行け 0234山師さん＠トレード中 (ﾜｯﾁｮｲ 3d8e-zM96)2017/11/03(金) 06:00:03.49ID:EybD/sFJ0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares has over 115 employees in the UK and 6 employees in Zurich. UK be relocating to the Cambridge area in "July 2018." The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline. ・・・ ※SOSE決算説明会：国際的なバイオ企業に成長するための中長期ビジネス戦略：直近12-18 ヶ月の見通し (5/12) ・Wave1のパイプラインが中期臨床開発段階へと進展："アデノシンA2AのPh1a 読み出し：2017年後半ごろ" ※ClinicalTrials: AZD4635, Phase 1, "Changes, Estimated Study Completion Date: 2017/10/12→2017/11/9". (7/18update) ※AstraZeneca Q2 2017: AZD4635 (A2AR): Solid tumours and Non-Small Cell Lung Cancer: Phase 1: "Data Anticipated: 2018". (7/27) ※Heptares Overview: Wave 2 Pipeline: "Multiple Candidates Entering Clinic from H2 2017", "mGlu5: 2017 Phase 1 SAD/MAD and PET Receptor Occupancy". (9/27update) ※MiNA: Seeking a Senior Research Scientist to join its Research Team Developing Novel Therapeutics. (10/14 Closed) ※MiNA: Seeking a Research Technician/Laboratory Manager to Join Its Research Team Developing Novel Therapeutics. (10/15 Closed) ※Heptares: Seeking an Molecular Biologist to Join the Protein Engineering Group at Our Site in Zurich Working. (10/15 Closed) ※ClinicalTrials: "AZD4635, Phase 1, Estimated Study Completion Date: 2017/11/9": Verified October 2017 by AstraZeneca. (10/18update) ※Heptares has Engaged Bio-Link to Identify Australian Expertise and Collaborators and Track Record of Clinical Translation of Developmental Drug Candidates. (10/20) ※MiNA: MiNA Research Featured as a HOT PAPER by OTS. "Novel Therapeutic in Clinical Trials for Liver Cancer." (10/23) ※Fiona Marshall: Excited to be Attending Zurich GPCR Day. ※Heptares: Some Great GPCR, GPCRs Science on Show Today. (10/25) ※Heptares Zurich: Seeking an Senior Protein Biochemist to Join Our Site in Zurich Working. "Closing 2017/11/15" (10/27) ※Pluristem: Upcoming: "Initiate pivotal trials, CLI in Japan", "Japan- Finalize Joint Venture" (10/29update) ※米国特許：CGRP Receptor Antagonists. (10/31公開) ※Allergan Q3 2017: Pipeline Highlights: Muscarinic Receptor M1: Ph 1, 2H 2017 and M4 Agonist: Entry Ph 1, 2H 2017. Rspectively: "Achieved" (11/1) ※MiNA: Innovate UK Awards Grant to MiNA Therapeutics and LGC LINK. (11/2) ・The Grant of Up to Approximately £400,000, with Additional Funding from MiNA and LGC LINK, will Support a Two-Year Research Project. ・Exciting New Area of Research in Collaboration with LGCGroup LINK. Develop Liver Directed Gene Activation Medicines. ・・・ ※AstraZeneca Year-to-date and Q3 2017 Results: (11/9) ※SOSEI 平成30年3月期第2四半期決算発表: (11/9) ・・・ 0235山師さん＠トレード中 (ﾜｯﾁｮｲ 3d8e-zM96)2017/11/03(金) 06:00:19.86ID:EybD/sFJ0 ※SOSEIの成長相場の動向： 2010/12/30 (終値_1350) 売残高_2740 買残高 _607100 ・(2010/10/15※最安値_650、2010/5/22最高値1545) 2011/12/30 (終値_1271) 売残高____0 買残高 _518100 ・(2011/3/15※最安値_693、2011/6/30最高値1680) 2012/12/21 (終値_2093) 売残高__100 買残高 _653600 ・(2012/6/6※最安値_950、2012/9/7最高値2967) 2013/12/20 (終値_4045) 売残高28500 買残高 _833300 ・(2013/1/4※最安値2050、2013/5/7最高値6100) 2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22※最安値1854、2014/9/8最高値6000: PfizerUK)※[成長回収期の入口]ステージへ 2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/2/21Heptares子会社化: 2015/3/16※最安値2851)※[成功の序章]ステージへ 2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24※安値3550) (2015/10/29※終値3885:Utibron･Seebri米国承認)※[次なる飛躍]ステージへ 2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(201511/30終値6060:Pfizer、12/1安値7060)※[上抜け圏]へ・(4/6終値14180:Allergan)※[強気相場] 2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/5/9最高値26180、6/24安値12960)※[強気相場解除]※[時間軸での調整局面]へ 2016/12/30 (終値13450) 売残高__300 買残高 2920000 ・(2016/12/8安値12470、1/24安値12910、2/13安値12400)※[時間軸調整は順調に推移] 2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(1/24安値12910、2/13安値12400、3/1安値10380)※[仕掛け、振るい場・拾い場]へ 2017/_6/30 (終値12350) 売残高_3600 買残高 1784800 ・(4/4安値10280、5/23安値10810、6/7安値10960)※[調整終盤での動意待ち] 2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(7/31安値11280、8/24,29安値8860、9/6※最安値8590)※[振るい・拾い場も順調に推移] 2017/10/27 (終値10230) 売残高__100 買残高 1644400 ・(10/4安値9090、10/10安値9570、10/23安値9820)※[時間軸調整終盤、予定通りに推移] 2017/11/_2 (終値11090) 5日線乖離(+4.96%) 25日線乖離(+11.64％) 75日線乖離(+11.18％) 200日線乖離(-1.23％) (安値10640) ・(10/31安値10170)
